VTAK · Flyte Aviation, Inc.

Catheter Precision's 2025 results showed robust revenue growth of 95% to $819 thousand, driven by commercialization milestones including CE Mark approval for LockeT in April 2025, first commercial sales in Europe, and addition of 32 new customers for VIVO and LockeT platforms. Gross margins improved slightly to 92.3%, reflecting operational efficiencies despite the net loss widening modestly to $17.2 million, of which $7.8 million was non-cash primarily from intangible impairments and debt extinguishment. Q4 revenue surged 60% to $238 thousand with stable margins at 91.6%. CEO David A. Jenkins highlighted customer expansion, European progress, and clinical validation as positioning the company for growth. Post-year-end, the acquisition of Flyte, Inc., a revenue-generating regional air mobility operator with Cirrus Vision Jets via FAA-certified Ponderosa Air, LLC, marks a strategic pivot into aviation, complemented by financing to bolster the balance sheet. This dual-platform strategy—medical devices (VIVO for ventricular arrhythmia mapping, LockeT for hemostasis) and aviation—targets large markets with catalysts like Flyte scaling, electrophysiology adoption, and strategic alternatives evaluation. Management views 2026 as primed for accelerated growth across segments, though non-GAAP reconciliations underscore ongoing cash expenses.